Abbildung 52: EUROPA-Studie - Perindopril - Benefit
In EUROPA study, all at-risk patients benefited, whether they were in low, medium or high risk group of patients. Perindopril 8 mg once daily reduced primary end-point (CV death, MI or cardiac arrest) regardless of age, gender, previous history of coronary artery disease (MI, CABG/PTCA, PVD, stroke), risk factors (smoking, diabetes) or preventive therapy (platelet inhibitors, lipid lowering drugs or B-blockers).